Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose Intravenous Administration of Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals - a Prospective, Multicenter, Open-label, Randomized Control Trial

NCT06762730 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT06762730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06762730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose Intravenous Administration of Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals - a Prospective, Multicenter, Open-label, Randomized Control Trial
Lead sponsor
Hadassah Medical Organization
Phase
Phase 4
Overall status
Recruiting
Start date
December 9, 2024
Completion date
December 1, 2032
Enrollment
110 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infected individuals, osteopenia